Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEEDS Trial
2022-500966-82-00Phase 3Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Oct 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, cisplatin, carboplatin, paclitaxel, folinic acid and 1 more in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Karolinska University Hospital. Primary endpoints: Overall survival and Health-related quality of life at 1 year. Planned start Oct 2023; status: authorised.
02
Drugs
fluorouracilcisplatincarboplatinpaclitaxelfolinic acid
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2022-500966-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500966-82-00.